Stenting And Thrombectomy Systems Fuel Neuro Device Market Growth
Executive Summary
Advances in distally protected carotid artery stenting systems and second-generation cerebral thrombectomy devices will help drive strong growth in the US neurointerventional device market over the next five years. The market, which includes endovascular devices for the treatment of cerebral aneurysms, arteriovenous malformations, stroke, and carotid artery disease, is projected to grow at a compound annual rate of 6.5%, and reach more than $846 million by 2018.
You may also be interested in...
Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.
Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.
Regulatory Flexibility: BrainStorm’s Problematic NurOwn BLA May Be A Bridge Too Far For US FDA
Litany of deficiencies, including product quality shortcomings and a failed Phase III clinical efficacy study, may make it impossible for the agency to exercise the type of flexibility it has with the approval of other treatments for ALS and neurodegenerative diseases.